TYMP; TP; ECGF; ECGF1; MNGIE; MEDPS1; MTDPS1; PDECGF; hPD-ECGF

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 22; NC_000022.11 (50525752..50530085, complement). Location: 22q13.33

Monoclonal

IgG2

(9A3)

Mouse

Lyophilized

Lyophilized samples are stable for 2 years from date of receipt when stored at -70 degree C. Reconstituted antibody can be aliquoted and stored frozen at < -20 degree C for at least for six months without detectable loss of activity.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-PD-ECGF antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

PD-ECGF, also known as TPase and gliostatin, is produced by placenta, platelets, liver, lung, spleen, lymph nodes, and peripheral lymphocytes. It is overexpressed by many tumors in response to chemical or physical stress. PD-ECGF promotes endothelial cell proliferation and chemotaxis and promotes angiogenesis. PD-ECGF is a key enzyme in the pyrimidine nucleoside salvage pathway. It also metabolizes and inactivates chemotherapeutic drugs such as 5-fluorouracil and its derivatives. The human PD-ECGF cDNA encodes a 482 amino acid (aa) polypeptide with a 10 aa propeptide. The protein is localized mostly within the producer cells. N-terminal truncation, resulting in proteins lacking 10 aa and 6 aa, has been observed in PD-ECGF purified from platelets and placenta, espectively. In solution, PD-ECGF exists as a non-disulfide linked homodimer. The latter protein was purified from quiescent astrocytes and described as an astrocyte and astrocytoma cell growth inhibitor based on its ability to inhibit 3H-thymidine incorporation.

Western Blot (WB)

49,955 Da

thymidine phosphorylase

thymidine phosphorylase; tdRPase; gliostatin

Thymidine phosphorylase

ECGF1; TP; PD-ECGF??[Similar Products]

TYPH_HUMAN

This gene encodes an angiogenic factor which promotes angiogenesis in vivo and stimulates the in vitro growth of a variety of endothelial cells. It has a highly restricted target cell specificity acting only on endothelial cells. Mutations in this gene have been associated with mitochondrial neurogastrointestinal encephalomyopathy. Multiple alternatively spliced transcript variants have been identified. [provided by RefSeq, Apr 2012]

Function: May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro. Ref.8Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. Ref.8

Catalytic activity: Thymidine + phosphate = thymine + 2-deoxy-alpha-D-ribose 1-phosphate.

Pathway: Pyrimidine metabolism; dTMP biosynthesis via salvage pathway; dTMP from thymine: step 1/2.

Subunit structure: Homodimer. Ref.10 Ref.11

Involvement in disease: Mitochondrial DNA depletion syndrome 1, MNGIE type (MTDPS1) [MIM:603041]: A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.13 Ref.14

Sequence similarities: Belongs to the thymidine/pyrimidine-nucleoside phosphorylase family.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.